Wendy Yarno left the role of Director at Iovance Biotherapeutics, Inc. As of November 14, 2026, Iovance Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 20, 2026, naming 1 departure (Form 8-K, March 20, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Iovance Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Iovance Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-20. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Iovance Biotherapeutics, Inc. files it.
Also on the record for Iovance Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.8% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.5% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.5% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.2% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.5% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Iovance Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Iovance Biotherapeutics, Inc. and the records around it.
Iovance Biotherapeutics, Inc. elsewhere on the record
Companies that share a holder
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2385 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Iovance Biotherapeutics, Inc.
Get an email when Iovance Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Iovance Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Iovance Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Iovance Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-20 | Out | Director | 8-K, 2026-03-20 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Wendy Yarno, Director (filed 2026-03-20):
The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company's operations, policies, or practices.
Who leads Iovance Biotherapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Wendy Yarno, departure reported (filed 2026-03-20). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Iovance Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Iovance Biotherapeutics, Inc., with the record behind each one.
Find candidates like Director at Iovance Biotherapeutics, Inc.Every change, in the filing's words
Departing: Wendy Yarno, Director
On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the " Board ") of Iovance Biotherapeutics, Inc. (the " Company "), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the " Annual Meeting ") currently anticipated to be held in June 2026.
- Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting.
- The Company thanks Ms. Yarno for her service to the Board.
Tools for this story
Each opens in a new tab, filled in for Iovance Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
